Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BLU-808 · 3 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| Arm A1 (Part A): BLU-808 | EXPERIMENTAL | BLU-808 will be administered orally. |
| Arm A3 (Part A): BLU-808 | EXPERIMENTAL | BLU-808 will be administered orally. |
| Arm B (Part B): BLU-808/Placebo | EXPERIMENTAL | BLU-808 or matching placebo will be administered orally. |
| BLU-808 Dose 1 | EXPERIMENTAL | BLU-808 will be administered orally for 28 days. |
| BLU-808 Dose 2 | EXPERIMENTAL | BLU-808 will be administered orally for 28 days. |
| Placebo | PLACEBO_COMPARATOR | Placebo will be administered orally for 28 days. |
| Part 1: BLU-808 | EXPERIMENTAL | BLU-808 will be administered orally. |
| Part 1: Placebo | PLACEBO_COMPARATOR | Matching placebo for BLU-808 will be administered orally. |
| Part 2: BLU-808 | EXPERIMENTAL | BLU-808 will be administered orally. |
| Part 2: Placebo | PLACEBO_COMPARATOR | Matching placebo for BLU-808 will be administered orally. |
| Part 2: Midazolam Alone Followed by BLU-808 and Midazolam | EXPERIMENTAL | Participants will receive oral midazolam in Period 1. Participants will then receive oral BLU-808 with midazolam in period 2. |
| Part 2: Midazolam Alone Followed by BLU-808 Matching Placebo and Midazolam | PLACEBO_COMPARATOR | Participants will receive oral midazolam in Period 1. Participants will then receive oral matching placebo for BLU-808 with midazolam in period 2. |
| Part 3: BLU-808 (Treatment D, E) | EXPERIMENTAL | BLU-808 will be administered orally. |
| Part 3: BLU-808 (Treatment E, D) | EXPERIMENTAL | BLU-808 will be administered orally. |
| Name | Type | Description |
|---|---|---|
| BLU-808 | DRUG | Oral administration |
| Placebo | DRUG | Oral administration |
| Midazolam | DRUG | Midazolam will be administered per schedule specified in the arm description. |
Key Inclusion Criteria: * Part A: Confirmed diagnosis of CIndU for ≥3 months prior to Day 1 that is inadequately controlled with second generation H1-antihistamines. * Part B: Confirmed diagnosis of CSU for ≥3 months prior to Day 1 that is inadequately controlled with second generation H1-antihista...
BLU-808 is an investigational small molecule being developed by Blueprint Medicines Corporation for allergic rhinoconjunctivitis, chronic inducible urticaria, and chronic spontaneous urticaria. It is also being studied in healthy participants. The drug is currently in Phase 2 clinical development for these conditions.
BLU-808 is a small molecule being developed by Blueprint Medicines Corporation. The specific molecular target of BLU-808 has not been disclosed in available clinical trial information. It is being studied for allergic rhinoconjunctivitis, chronic inducible urticaria, and chronic spontaneous urticaria.
BLU-808 is being developed by Blueprint Medicines Corporation, a biopharmaceutical company traded on the Nasdaq under the ticker symbol BPMC. The company is conducting clinical trials of BLU-808 for allergic rhinoconjunctivitis, chronic inducible urticaria, and chronic spontaneous urticaria.
BLU-808 is in Phase 2 clinical development. It has completed a Phase 1 study in healthy participants and a Phase 2 study in allergic rhinoconjunctivitis. A Phase 2 study in chronic inducible urticaria and chronic spontaneous urticaria is active but not recruiting. BLU-808 is investigational and not yet approved.
BLU-808 has been studied in three clinical trials. NCT06922448 is a completed Phase 2 study in allergic rhinoconjunctivitis. NCT06931405 is an active Phase 2 study in chronic inducible urticaria and chronic spontaneous urticaria. NCT06948032 is a completed Phase 1 study in healthy participants.
BLU-808 is the only name provided for this investigational drug. No alternative names have been disclosed in the available clinical trial information. It is being developed by Blueprint Medicines Corporation for allergic rhinoconjunctivitis, chronic inducible urticaria, and chronic spontaneous urticaria.